Biogen Inc. (BIIB)

• Annual Data
• Quarterly Data

Biogen Inc., Common-Size Consolidated Income Statement (quarterly data)

	3 months ended	Mar 31, 2019		Dec 31, 2018		Sep 30, 2018		Jun 30, 2018		Mar 31, 2018		Dec 31, 2017		Sep 30, 2017		Jun 30, 2017		Mar 31, 2017		Dec 31, 2016		Sep 30, 2016		Jun 30, 2016		Mar 31, 2016		Dec 31, 2015		Sep 30, 2015		Jun 30, 2015		Mar 31, 2015		Dec 31, 2014		Sep 30, 2014		Jun 30, 2014		Mar 31, 2014
	Product, net
	Revenues from anti-CD20 therapeutic programs
	Other
	Revenues
	Cost of sales, excluding amortization and impairment of acquired intangible assets
	Gross profit
	Research and development
	Selling, general and administrative
	Loss on assets and liabilities held for sale
	Amortization and impairment of acquired intangible assets
	Collaboration (profit) loss sharing
	Acquired in-process research and development
	Gain (loss) on fair value remeasurement of contingent consideration
	Restructuring charges
	TECFIDERA litigation settlement and license charges
	Gain on sale of rights
	Income from operations
	Other income (expense), net
	Income before income tax expense and equity in loss of investee, net of tax
	Income tax expense
	Equity in loss of investee, net of tax
	Net income
	Net (income) loss attributable to noncontrolling interests, net of tax
	Net income attributable to Biogen Inc.

Based on: 10-Q (filing date: 2019-04-24), 10-K (filing date: 2019-02-06), 10-Q (filing date: 2018-10-23), 10-Q (filing date: 2018-07-24), 10-Q (filing date: 2018-04-24), 10-K (filing date: 2018-02-01), 10-Q (filing date: 2017-10-24), 10-Q (filing date: 2017-07-25), 10-Q (filing date: 2017-04-25), 10-K (filing date: 2017-02-02), 10-Q (filing date: 2016-10-26), 10-Q (filing date: 2016-07-21), 10-Q (filing date: 2016-04-21), 10-K (filing date: 2016-02-03), 10-Q (filing date: 2015-10-21), 10-Q (filing date: 2015-07-24), 10-Q (filing date: 2015-04-24), 10-K (filing date: 2015-02-04), 10-Q (filing date: 2014-10-22), 10-Q (filing date: 2014-07-23), 10-Q (filing date: 2014-04-23).